ABBV — AbbVie Inc.

AbbVie Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Earnings Per Share (EPS): $10 for the full year, exceeding guidance by $0.54.
• Total Net Revenues: $61.2 billion for the year, surpassing initial guidance by over $2 billion, with an 8.6% sales growth.
• Q4 Adjusted EPS: $2.71, $0.08 above guidance.
• Q4 Total Net Revenues: $16.6 billion, reflecting a 10% growth.
• Adjusted Gross Margin: 83.6% of sales.
• R&D Expense: Adjusted R&D expense was 15.4% of sales, totaling nearly $9.7 billion for 2026.
• Free Cash Flow: Expected to be $18.5 billion in 2026.

2. Strategic Updates and Business Highlights

• Pipeline Development: AbbVie advanced 90 clinical programs, with several new product approvals including RINVOQ for GCA and EMERALIS for lung cancer.
• Business Development: Invested over $5 billion in new business development, acquiring innovative technologies and products, including a CAR T platform and a next-generation psychedelic for depression.
• Oncology Portfolio: Strengthened with new acquisitions, including a PD-1 VEGF bispecific antibody.
• Neuroscience Growth: Notable growth in Vraylar and the launch of Violet for Parkinson's disease, expected to achieve blockbuster status in 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected total sales growth of 9.5%, with total net revenues projected around $67 billion.
• Key Product Forecasts:
  • Immunology sales expected at $34.5 billion.
  • Neuroscience sales projected at $12.5 billion.
  • Oncology sales anticipated at $6.5 billion.
  • Aesthetics sales expected at $5 billion.
• Adjusted EPS Guidance for 2026: Between $14.37 and $14.57.

4. Bad News, Challenges, or Points of Concern

• HUMIRA Erosion: Experienced nearly $16 billion in revenue erosion due to biosimilar competition, with expectations for further declines in 2026.
• Pricing Pressures: Anticipated low single-digit pricing headwinds for SKYRIZI and RINVOQ in 2026.
• Competitive Pressures: Increasing competition in immunology, particularly with new entrants in the IBD market, could impact SKYRIZI's market share.
• Oncology Challenges: IMBRUVICA faced a 20.8% decline in sales due to competitive dynamics and IRA pricing impacts.

5. Notable Q&A Insights

• Immunology Franchise: SKYRIZI's performance remains strong despite competition, with high capture rates in the IBD market. AbbVie is confident in its growth potential, bolstered by upcoming data readouts.
• Business Development Strategy: AbbVie is open to both early and late-stage asset acquisitions to enhance its pipeline, focusing on immunology, neuroscience, and oncology.
• Migraine Market Expansion: AbbVie is expanding its presence in primary care for migraine treatments, with strong performance from UBRELVY and QLIPTA.
• Regulatory and Competitive Landscape: Concerns were raised about potential competition from IL-15 therapies in vitiligo, but AbbVie remains optimistic about RINVOQ’s positioning in the market.

This summary encapsulates AbbVie's strong performance in 2025, strategic advancements, and the challenges ahead as they navigate a competitive landscape while maintaining growth momentum.